What is the primary impact of the Guidant acquisition on the company's financial statements?

The Guidant acquisition is a major event impacting the financial statements through significant acquisition-related expenses, integration costs, and increased debt levels on the balance sheet. These factors contributed to the reported net loss for the quarter.

How is the company performing operationally, excluding acquisition-related costs?

While the filing reports a net loss, investors should analyze the 'Management's Discussion and Analysis' section for details on revenue performance by product segment and region to understand the underlying operational trends and the health of the core business.

What are the key risks highlighted in this filing?

The key risks include the successful integration of the Guidant acquisition, the ongoing financial and reputational impact of legal proceedings, and potential challenges in the broader economic environment affecting demand for medical devices.

What should investors look for in the balance sheet?

Investors should scrutinize the balance sheet for the company's debt levels, particularly as a result of financing the Guidant acquisition, and assess its liquidity position and ability to manage its financial obligations.

BSX 10-Q Quarterly Report Q2 FY2009 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation's (BSX) 10-Q filing for the period ending June 29, 2009, reveals a company navigating a challenging economic environment while undertaking significant strategic initiatives, most notably the pending acquisition of Guidant Corporation. The company reported a net loss for the quarter, impacted by substantial acquisition-related expenses and integration costs associated with Guidant. Despite the headline loss, the underlying operational performance requires careful examination. Investors should focus on revenue trends across key product segments and geographical regions, as well as the company's ability to manage its debt burden and integrate the Guidant acquisition effectively. The filing also highlights ongoing litigation, which continues to pose a risk to the company's financial stability and reputation.

Financial Highlights

46 data points

Beta

Revenue

$2.07B

0.7% Gross Margin

Net Income

$158.00M

0.1% Net Margin

EPS (Diluted)

$0.10

Total Assets

$26.19B

Cash & Equivalents

$1.19B

Free Cash Flow

$345.00M

Financial Statements

Beta

Revenue	$2.07B
Cost of Revenue	$630.00M
Gross Profit	$1.44B
SG&A Expenses	$671.00M
Operating Expenses	$1.17B
Operating Income	$275.00M
Interest Expense	$92.00M
Net Income	$158.00M
EPS (Basic)	$0.10
EPS (Diluted)	$0.10
Shares Outstanding (Basic)	1.51B
Shares Outstanding (Diluted)	1.51B

Key Highlights

1Reported a net loss for the quarter, influenced by acquisition costs and integration expenses related to the Guidant acquisition.
2The pending acquisition of Guidant Corporation remains a central focus, with significant financial and operational implications.
3Management commentary will likely detail revenue performance by product line and geography, crucial for understanding underlying operational health.
4The company's balance sheet will reflect the impact of debt taken on for the Guidant acquisition, requiring investor scrutiny of leverage ratios.
5Ongoing legal proceedings, particularly those related to product liability, continue to represent a material risk factor.
6Cash flow from operations should be monitored to assess the company's ability to generate cash internally amidst strategic investments and potential litigation payouts.

BOSTON SCIENTIFIC CORP Quarterly Report for Q2 Ended Jun 30, 2009

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions